Theresa Vitelle's questions to Alnylam Pharmaceuticals Inc (ALNY) leadership • Q4 2024
Question
Theresa Vitelle, on for Greg Harrison, asked about the expected revenue mix for vutrisiran (AMVUTTRA) between naive patients versus those switching from other therapies.
Answer
Chief Commercial Officer Tolga Tanguler stated that while the company provided ambitious guidance, it would not break down the specific mix. He noted that AMVUTTRA is well-positioned to be a first-line standard of care but also expects a good mix of naive patients and switches from stabilizers, with all elements incorporated into their financial guidance.